The aberrant tumor immunity is the foundation of today’s immune-oncology (IO) therapies, including immune checkpoint inhibitors (ICIs)3,4, e.g., anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody treatments, which block the intrinsic suppression of tumor immunity. Here, CTLA4 is linked to neoplasm.